Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Corpea
2. Corvaton
3. Duracoron
4. Fali Cor
5. Fali-cor
6. Heumann, Molsidomin
7. Korvatone
8. Molsi 1a Pharma
9. Molsi Azu
10. Molsi Puren
11. Molsi-azu
12. Molsi-puren
13. Molsibeta
14. Molsicor
15. Molsidain
16. Molsidomin
17. Molsidomin Heumann
18. Molsidomin Ratiopharm
19. Molsidomin Stada
20. Molsidomin Von Ct
21. Molsidomin-ratiopharm
22. Molsihexal
23. Molsiket
24. Morsydomine
25. Mtw Molsidomin
26. Mtw-molsidomin
27. Sin 10
28. Sin-10
29. Sin10
30. Sydnopharm
31. Von Ct, Molsidomin
1. 25717-80-0
2. Morsydomine
3. Corvaton
4. Motazomin
5. Molsidolat
6. Sin-10
7. Morial
8. N-ethoxycarbonyl-3-morpholinosydnonimine
9. Cas 276
10. Mls000028573
11. Sydnone Imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-
12. N-carboxy-3-morpholinosydnone Imine Ethyl Ester
13. (1e)-1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
14. Smr000058990
15. Sydnopharm
16. Cas-276
17. D46583g77x
18. Nsc-757398
19. N-carboxy-3-morpholinosydnonimine Ethyl Ester
20. Ncgc00015661-02
21. Cas-25717-80-0
22. N-(ethoxycarbonyl)-3-(4-morpholinyl)sydnone Imine
23. N-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]carbamic Acid Ethyl Ester
24. Sydnone Imine, N-carboxy-3-morpholino-, Ethyl Ester
25. Dsstox_cid_25171
26. Dsstox_rid_80721
27. Dsstox_gsid_45171
28. Molsidomina
29. Molsidominum
30. Covarsal
31. Molsidominum [inn-latin]
32. Molsidomina [inn-spanish]
33. Sr-05000001464
34. Einecs 247-207-4
35. Brn 3999414
36. Unii-d46583g77x
37. Ethyl (nz)-n-(3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-ylidene)carbamate
38. Molsidomine [usan:inn:ban:jan]
39. N-(ethoxycarbonyl)-3-(4-morpholino)sydnone Imine
40. Prestwick_863
41. Mfcd00869301
42. Opera_id_238
43. Molsidomine [mi]
44. Prestwick3_000547
45. Lopac-m-2901
46. Molsidomine [inn]
47. Molsidomine [jan]
48. Molsidomine [usan]
49. Molsidomine [mart.]
50. Schembl34019
51. Bspbio_000593
52. Molsidomine [who-dd]
53. Mls001146942
54. Mls002153869
55. Spectrum1500673
56. Molsidomine (jan/usan/inn)
57. Bpbio1_000653
58. Chembl1256353
59. Chembl1329455
60. Chembl4059924
61. Dtxsid0045171
62. Bdbm39912
63. Chebi:92623
64. Cid_5353788
65. Hms501o05
66. Hms1569n15
67. Hms1921a16
68. Hms2089l03
69. Hms2092g20
70. Hms2096n15
71. Hms2232f20
72. Hms2235b12
73. Hms3262a12
74. Hms3649m16
75. Hms3713n15
76. Molsidomine [ep Monograph]
77. Hy-b1069
78. Molsidomine 1.0 Mg/ml In Methanol
79. Tox21_110192
80. Tox21_500725
81. Bdbm50248123
82. Ccg-40069
83. S4664
84. Akos015843340
85. Akos015900360
86. Akos015962928
87. Akos026749793
88. Tox21_110192_1
89. Ac-7473
90. Ccg-220547
91. Cs-4625
92. Db09282
93. Ks-5160
94. Nsc 757398
95. Sdccgsbi-0050703.p005
96. Ncgc00015661-01
97. Ncgc00015661-03
98. Ncgc00015661-04
99. Ncgc00015661-05
100. Ncgc00015661-06
101. Ncgc00015661-07
102. Ncgc00015661-08
103. Ncgc00015661-09
104. Ncgc00015661-10
105. Ncgc00015661-12
106. Ncgc00015661-16
107. Ncgc00024136-03
108. Ncgc00024136-04
109. Ncgc00024136-05
110. Ncgc00024136-06
111. Ncgc00024136-07
112. Ncgc00261410-01
113. Smr001233224
114. Sbi-0050703.p004
115. Ab00513859
116. Eu-0100725
117. D01320
118. Ab00052152_14
119. Ab00513859-02
120. A817988
121. Sr-05000001464-1
122. Sr-05000001464-3
123. W-107222
124. (1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)formimidate
125. (ethoxycarbonyl)(3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide
126. 1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
127. (1e)-1-ethoxy-n-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]methanimidate
128. (1e)-1-ethoxy-n-(3-morpholin-4-yl-1,2,3-oxadiazol-3-ium-5-yl)methanimidate
129. (1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)methanimidate;molsidomine
| Molecular Weight | 242.23 g/mol |
|---|---|
| Molecular Formula | C9H14N4O4 |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 242.10150494 g/mol |
| Monoisotopic Mass | 242.10150494 g/mol |
| Topological Polar Surface Area | 87 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 270 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension.
Molsidomine leads to smooth muscle relaxation in the coronary blood vessels, relieving symptoms of angina and increasing blood flow to the coronary arteries.
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Nitric Oxide Donors
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) (See all compounds classified as Nitric Oxide Donors.)
C - Cardiovascular system
C01 - Cardiac therapy
C01D - Vasodilators used in cardiac diseases
C01DX - Other vasodilators used in cardiac diseases
C01DX12 - Molsidomine
Absorption
Peak plasma drug concentration (tmax) occurs from 1 to 2 hours after administration.
Volume of Distribution
98 L
Clearance
renal excretion is the main route of elimination of the metabolites in humans (90% to 95%) About 2% of the ingested drug is excreted unchanged in the urine.
Molsidomine hepatically metabolized to _linsidomine_. Linsidomine releases nitric oxide (NO) from endothelial cells when it decays, and acts as the active vasodilating metabolite responsible for molsidomine's pharmacological effects. Oral absorption of Molsidomine is found to be 95.5% 4.5. Presystemic metabolism is noted to be 56% and metabolism is reported extensive by Liver. Renal Excretion accounts for 95 % and plasma half-life is 5 hr. Back to top
Molsidomine, a cardiovascular drug, acts in a similar fashion to organic nitrates. The SIN-1A metabolite of molsidomine has a pharmacologically active group of nitric oxide, which increases levels of cyclic GMP, and decreases intracellular calcium ions in smooth muscle cells. This leads to relaxation of smooth muscle in the blood vessels, and inhibits platelet aggregation.
API SUPPLIERS
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
Certificate Number : CEP 2017-021 - Rev 01
Issue Date : 2024-03-25
Type : Chemical
Substance Number : 1701
Status : Valid
Registrant Name : Erison Pharmaceutical Co., Ltd.
Registration Date : 2020-12-14
Registration Number : 20201214-209-J-658
Manufacturer Name : Zaklady Farmaceutyczne Polpharma SA
Manufacturer Address : Annopol 6, 03-236 Warszawa, Poland
| Available Reg Filing : ASMF |
Certificate Number : CEP 2017-214 - Rev 01
Issue Date : 2024-01-05
Type : Chemical
Substance Number : 1701
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Listed Suppliers
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
About the Company : Polpharma API. European CDMO partner and API manufacturer since 1951. Poland-based CDMO and API producer, delivering products to pharmaceutical companies worldwide. Aiming at the c...
About the Company : We can help your company solve the payment problems during the trading from chinese factories. We supply you with OEM from china.We are professsionals with the competitive price an...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Global Sales Information
Finished Drug Prices
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Ret Tabl
Dosage Strength : 8mg
Price Per Pack (Euro) : 3.5
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Ret Tabl
Dosage Strength : 8mg
Price Per Pack (Euro) : 10.92
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Tabl
Dosage Strength : 2mg
Price Per Pack (Euro) : 2.71
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Tabl
Dosage Strength : 2mg
Price Per Pack (Euro) : 6.24
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Tabl
Dosage Strength : 4mg
Price Per Pack (Euro) : 2.96
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
RX/OTC/DISCN : Class B
CPS Cito Pharma Services GmbH
Dosage Form : Tabl
Dosage Strength : 4mg
Price Per Pack (Euro) : 8.44
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
